3 results
Approved WMOCompleted
1. To assess the effect of odanacatib 50 mg once weekly versus placebo on lumbar spine BMD over 24 months.2. To assess the safety and tolerability of odanacatib 50 mg once weekly compared to placebo.
Approved WMOCompleted
The objective of the AUGMENT-HF study is to provide evidence for the safety profile associated with the Algisyl-LVR* device and initial evidence for the efficacy of the device.
Approved WMORecruiting
The objective is to investigate if there is a flow-dependent effect of HFNC on ventilation during an EBUS procedure under procedural sedation in patients with COPD gold class 3-4.